Featuring Evidence From
Why now
The "no measurable AI impact" headline is reading lagging data.
For two years, the dominant narrative has been that organisations adopt GenAI but see no measurable impact. That narrative is becoming outdated.
A new study by Oliver Wyman, Unlocking the Great Health Productivity Reset, developed with Harvard Medical School and Fraunhofer IPA, analyses 200 real-world AI use cases across pharma, medtech, clinical care and insurance. The conclusion is direct: productivity gains are real, they are quantifiable, and the gap between leaders and laggards is widening fast.
The difference between a 4% incremental cost reduction and a 22% productivity breakthrough is not technology access. It is execution discipline, and reaching the breakthrough requires only 30% more investment for 82% more savings.
For pharma commercial leaders and Chief AI Officers the question is no longer whether AI works. It is which use cases compound, and which stay stuck in pilot. This masterclass focuses on exactly that distinction.
What you'll take away
Frameworks and benchmarks for your leadership team. The same week.
01
A clear, evidence-based view of where AI creates real productivity in pharma, and where it does not.
02
An honest diagnosis of why adoption stalls in commercial organisations, beyond the usual change-management clichés.
03
A concrete look at AI coaching as a high-leverage entry point: measurable, scalable, tied to commercial KPIs.
04
Numbers and frameworks you can take into your next leadership conversation, the same week.
Agenda · 40 minutes
A focused session. No filler.
15:00
15 min · Keynote
The productivity reset is already happening
Dr. Oliver Eitelwein · Oliver Wyman
What the new Oliver Wyman study (with Harvard Medical School and Fraunhofer IPA) found across 200 use cases
Why "no measurable AI impact" headlines are reading lagging data
The three adoption pathways, and why halfway efforts are the most expensive option
15:15
10 min · Discussion
Where pharma commercial teams capture real gains
Joint discussion · Oliver Eitelwein and Dr. Patrick Oehler
What separates the 22% breakthrough scenario from the 4% incremental one
Why workforce enablement and human skills are where commercial productivity actually compounds
The adoption gap: why field teams resist, and what reframes the conversation
15:25
10 min · Applied
AI coaching as a low-friction entry point
Dr. Patrick Oehler · Retorio
Why HCP-facing conversations are the highest-leverage place to apply AI in pharma commercial
How leading pharma teams train at scale on MLR-approved content, with measurable behavioural lift
A short live look at what good looks like, and what the data says about ROI
15:35
10 min · Q&A
Live Q&A with both speakers
Submit questions live or in advance during registration
Speakers
The macro evidence and the practical entry point.
Macro evidence
Dr. Oliver Eitelwein
Partner & Global Head Performance Transformation Life Sciences, Oliver Wyman
Lead author of Unlocking the Great Health Productivity Reset (2026), Oliver Wyman's research on AI productivity in healthcare, developed with Harvard Medical School and Fraunhofer IPA, Europe's largest applied research institution.
Applied use case
Dr. Patrick Oehler
Co-founder & CEO, Retorio
Behavioural science researcher turned founder. Retorio's AI coaching platform is used by leading global pharma, automotive and insurance companies, including Merck, Amgen and Madrigal, to train customer-facing teams at scale.